Based on these findings, FDA approval of pembrolizumab monotherapy as a first-line treatment was extended to patients with locally advanced (stage III) or metastatic, EGFR/ALK wild-type NSCLC and with PD-L1 TPS ≥ 1% as determined by an FDA-approved test (72). This evidence concerns the gene ALK and non-small cell lung carcinoma.